Thelansis

Bachmann–Bupp Syndrome (BABS) Market Outlook Thelansis’s “Bachmann–Bupp Syndrome (BABS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bachmann–Bupp Syndrome (BABS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

Bachmann–Bupp Syndrome (BABS) Market Outlook Thelansis’s “Bachmann–Bupp Syndrome (BABS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bachmann–Bupp Syndrome (BABS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Bachmann–Bupp Syndrome (BABS) Overview Bachmann–Bupp syndrome (BABS) is an autosomal dominant genetic disorder caused by heterozygous de novo gain-of function pathogenic variants in the ornithine decarboxylase 1 (ODC1) gene located on chromosome 2p25.1. These variants result in increased polyamines, causing abnormalities of functions such as angiogenesis, carcinogenesis, and embryogenesis. Currently, there are nine h...

 Bachmann–Bupp syndrome (BABS) is an autosomal dominant genetic disorder caused by heterozygous de novo gain-of function pathogenic variants in the ornithine decarboxylase 1 (ODC1) gene located on chromosome 2p25.1. These variants result in increased polyamines, causing abnormalities of functions such as angiogenesis, carcinogenesis, and embryogenesis. Currently, there are nine humans reported having ODC1 pathogenic variants. Features which are shared amongst these individuals include polyhydramnios, broad forehead/macrocephaly, neuroimaging abnormalities with no particular pattern, global developmental delay, cryptorchidism in male patients, and muscular hypotonia. The patient presented at 11 months of age with near-total alopecia of the scalp, eyebrows, eyelashes and curved, brittle fingernails. Around age one year, she started developing pustules and cysts on the posterior scalp and back. Five larger lesions became erythematous and tender, resulting in rupture and ultimately req...